Global biotechnology group Genzyme says it is increasing its headcount in the UK after buying back the rights to the leukaemia drug Campath/MabCampath (alemtuzumab) from Bayer HealthCare.

The move, plus the acquisition of two further cancer products from Bayer - Fludara (fludarabine) and Leukine (sargramostim) - substantially expands the group’s oncology portfolio, and has thereby generated the need for a number of new jobs within Genzyme’s Transplant & Oncology unit at its UK headquarters in Oxford.

Eleven new roles have been created to add to the group’s 600-strong workforce in the UK, including Marketing and Product Managers covering its haematology and oncology portfolio, product and commissioning specialists and a Medical Science Liaison person, positions which Genzyme UK says it expects to fill by September.

According to Rory Cameron, Business Unit Director of Transplant & Oncology for Genzyme UK & Ireland, the new products purchased through the transaction with Bayer “significantly expand” the firm’s presence in the haematologic malignancies field, and bring “the opportunity to grow what is already a fast developing part of our business in the UK and Ireland”.